GENESIS Biomed and FI Group create GENESIS Tech Transfer Boost, a new investment vehicle that will invest in early stage projects from healthcare research

The consultancy firms GENESIS Biomed and FI Group, leaders in biomedical strategic consultancy and in advising on the financing of R&D&I and the management of calls for public grants and funding, respectively, have created GENESIS Tech Transfer Boost, a new investment vehicle initially endowed with €1M that will invest in early stage projects in the field of health research.

GENESIS Tech Transfer Boost will invest tickets from 25k to 100k per project, in exchange for equity in the companies already created, or in exchange for an equity commitment in the projects that will become spin-offs at a later stage. This funding will be aimed at generating maximum value in the projects invested, from the generation of key proofs of concept to patent protection of the results, including the preparation of the business plan and the application for regional, national, and international public funding. The investment focus will be very cross-cutting, including pharma, Medtech, diagnostics and digital health projects.

The vehicle has been created thanks to the synergy between the consulting firms GENESIS Biomed and FI Group, which have been collaborating for several years with several common success stories, such as the companies Corify Care, CreatSens, Cornea Project, Oxolife, Telara Pharma, Aortyx, Mowoot, ADmit Therapeutics, Endolipid Therapeutics, AptaTargets and Anais Medical, among others. 

The company Crowd4Ventures, led by Agustí Soler, has also participated in the constitution of the vehicle. 

This new vehicle will base its scouting on all projects coming from the main Health Research Institutes in Spain, as well as from the nodes of the ITEMAS network. 

This investment model has already been previously validated by the vehicle that the consulting firm GENESIS Biomed created in 2017, called GENESIS Ventures, which has invested in 14 biomedical projects and the valuation portfolio has reached a multiplier of x3.5 in 4 years